Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) Net Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Net Margin for 5 consecutive years, with 69.26% as the latest value for Q2 2024.

  • Quarterly Net Margin rose 277187.0% to 69.26% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 0.64% through Mar 2025, up 396056.0% year-over-year, with the annual reading at 12.16% for FY2024, 345790.0% up from the prior year.
  • Net Margin for Q2 2024 was 69.26% at Fulcrum Therapeutics, up from 2842.25% in the prior quarter.
  • The five-year high for Net Margin was 69.26% in Q2 2024, with the low at 8399.66% in Q1 2023.
  • Average Net Margin over 5 years is 1885.27%, with a median of 1026.08% recorded in 2020.
  • The sharpest move saw Net Margin plummeted -739935bps in 2023, then soared 277187bps in 2024.
  • Over 5 years, Net Margin stood at 419.41% in 2020, then dropped by -11bps to 464.29% in 2021, then crashed by -722bps to 3815.33% in 2022, then increased by 26bps to 2842.25% in 2023, then surged by 102bps to 69.26% in 2024.
  • According to Business Quant data, Net Margin over the past three periods came in at 69.26%, 2842.25%, and 3164.3% for Q2 2024, Q4 2023, and Q3 2023 respectively.